CPAP
DeviceAutomatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
NCT Number: NCT03812653
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
University of Alabama Hospital, Birmingham, Alabama, United States
Sleep SMART has a prospective, randomized, open-label, blinded-endpoint (PROBE) design. It is a multi-site, parallel-group superiority trial that compares 6 months of OSA treatment to usual care. The study includes two trials: a prevention study with an embedded recovery trial. 3062 subjects will be randomized over 5 years at 110 sites within the NINDS-funded StrokeNet clinical trials network.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Current Inclusion Criteria, as of 6/28/2024:
Previous Inclusion Criteria, prior to 6/28/2024:
Exclusion criteria
(for entire time period):
Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
Time frame: 6 months post randomization
The primary outcome is a time-to-event outcome defined as a participant having at least one of the following events within 6-months from randomization: new ischemic stroke, acute coronary syndrome or all-cause mortality
Time frame: 3 months post randomization
Functional outcome as measured by the 9 question modified Rankin Scale (mRS-9Q). The mRS-9Q has 9 questions related to level of function. Outcomes range from 0 (no symptoms) to 6 (death).
Time frame: 3 months post randomization
Neurological outcome is measured by the NIHSS. The NIHSS scale ranges from 0 (no deficits) to 42.
Time frame: 3 months post randomization
Cognitive outcome is measured by the Short MoCA. The short MoCA is a 5 minute short version of the Montreal Cognitive Assessment (MoCA). This instrument tests phonemic verbal fluency (1 point), delayed recall (5 points), and orientation (6 points) with a score ranging from 0-12.
Time frame: 3 months post randomization
Quality of life outcome is measured by the shortened Stroke Specific Quality of Life Scale (SS-QOL). The short SS-QOL has 7 domains that include physical function, language, vision, thinking, energy, mood, and role function. There is 1 question from each domain. The 12 item SS-QOL is calculated by averaging the scores of these 12 questions.
University of Michigan
Other
Acronym: Sleep SMART
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01703663
Apnea, Brain Diseases
Ann Arbor, Michigan, United States
View Trial DetailsNCT06011720
Brain Diseases, Brain Ischemia
New Brunswick, New Jersey, United States
View Trial DetailsNCT07649135
Behavior, Brain Diseases
Minneapolis, Minnesota, United States
View Trial DetailsNCT07553650
Brain Diseases, Brain Infarction
Hamburg, Free and Hanseatic City of Hamburg, Germany
View Trial Details